I'd go so far as to say this could be a strategic relationship as the years go by. Two of the partners behind Cartherics (and all but one of the other entities too) research are at the bleeding edge of the technology. These may be just the first 2 cancer types they are targeting, if it goes somewhere who knows just how diverse this off the shelf treatment will become.
https://cartherics.com.au/about-us/
When I first saw the grant approval months ago there was close to no info to go on other than in the grant description and that Mesoblast was in the mix.
I'm pretty happy about the announcement too.
Ann: Partnership For Allogeneic Cell-based Cancer Immunotherapies, page-13
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |